Mobilization of endogenous bone marrow-derived stem cells in a thioacetamide-induced mouse model of liver fibrosis

Tissue and Cell

Volumn 47, Issue 3, 2015, Pages 257-265

  El Akabawy, Gehan ^a   El Mehi, Abeer ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

Author keywords

CD34 positive cells; Histopathology; Liver cirrhosis; StemEnhance; Thioacetamide

Indexed keywords

CD34 ANTIGEN; NATURAL PRODUCT; STEMENCHANCE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; GRANULOCYTE COLONY STIMULATING FACTOR; THIOACETAMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELL; HISTOPATHOLOGY; IMMOBILIZED CELL; LIVER FIBROSIS; LIVER FUNCTION; MALE; MOUSE; NONHUMAN; PERIPHERAL CIRCULATION; UPREGULATION; ANIMAL; BIOSYNTHESIS; BONE MARROW CELL; CHEMICALLY INDUCED; DISEASE MODEL; GENETICS; HUMAN; LIVER; LIVER CIRRHOSIS; PATHOLOGY;

ANIMALS; ANTIGENS, CD34; BONE MARROW CELLS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; HUMANS; LIVER; LIVER CIRRHOSIS; MICE; THIOACETAMIDE; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84930090648     PISSN: 00408166     EISSN: 15323072     Source Type: Journal    
DOI: 10.1016/j.tice.2015.03.003     Document Type: Article

References (54)

1. Agaev B., Agaev R., Popandopoulo A., Jafarli R. Clinical efficacy of autologous mesenclyme multipotential stem cells transplantation in the liver cirrhosis and portal hypertension treatment. Georgian Med. News 2014, 39-45.
2. Aini W., Miyagawa-Hayashino A., Ozeki M., Adeeb S., Hirata M., Tamaki K., Uemoto S., Haga H. Accelerated telomere reduction and hepatocyte senescence in tolerated human liver allografts. Transpl. Immunol. 2014, 31:55-59.
3. Ali G., Masoud M.S. Bone marrow cells ameliorate liver fibrosis and express albumin after transplantation in CCl(4)-induced fibrotic liver. Saudi J. Gastroenterol. 2012, 18:263-267.
4. Barnes G., Pathak A., Schwartzberg L. G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use. Cancer Med. 2014, 3:1477-1484.
5. Bensinger W.I., Buckner C.D., Rowley S., Storb R., Appelbaum F.R. Treatment of normal donors with recombinant growth factors for transplantation of allogeneic blood stem cells. Bone Marrow Transplant. 1996, 17(Suppl. 2):S19L 21.
6. Cho K.A., Lim G.W., Joo S.Y., Woo S.Y., Seoh J.Y., Cho S.J., Han H.S., Ryu K.H. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Liver Int. 2011, 31:932-939.
7. Cui S., Hano H., Sakata A., Harada T., Liu T., Takai S., Ushigome S. Enhanced CD34 expression of sinusoid-like vascular endothelial cells in hepatocellular carcinoma. Pathol. Int. 1996, 46:751-756.
8. Dalakas E., Newsome P.N., Harrison D.J., Plevris J.N. Hematopoietic stem cell trafficking in liver injury. FASEB J. 2005, 19:1225-1231.
9. Drapeau C., Antarr D., Ma H., Yang Z., Tang L., Hoffman R.M., Schaeffer D.J. Mobilization of bone marrow stem cells with StemEnhance improves muscle regeneration in cardiotoxin-induced muscle injury. Cell Cycle 2010, 9:1819-1823.
10. Dhingra A., Kapoor S., Alqahtani S.A. Recent advances in the treatment of hepatitis C. Discov. Med. 2014, 18:203-208.
11. Duan X.Z., Liu F.F., Tong J.J., Yang H.Z., Chen J., Liu X.Y., Mao Y.L., Xin S.J., Hu J.H. Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure. World J. Gastroenterol. 2013, 19:1104-1110.
12. D'Souza A., Jaiyesimi I., Trainor L., Venuturumili P. Granulocyte colony-stimulating factor administration: adverse events. Transfus. Med. Rev. 2008, 22:280-290.
13. El-Ansary M., Abdel-Aziz I., Mogawer S., Abdel-Hamid S., Hammam O., Teaema S., Wahdan M. Phase II trial: undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis. Stem Cell Rev. 2012, 8:972-981.
14. Friedman S.L., Sheppard D., Duffield J.S., Violette S. Therapy for fibrotic diseases: nearing the starting line. Sci. Transl. Med. 2013, 5:167sr161.
15. Garg V., Garg H., Khan A., Trehanpati N., Kumar A., Sharma B.C., Sakhuja P., Sarin S.K. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology 2012, 142. 505-512.e1.
16. Gaia S., Smedile A., Omede P., Olivero A., Sanavio F., Balzola F., Ottobrelli A., Abate M.L., Marzano A., Rizzetto M., Tarella C. Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease. J. Hepatol. 2006, 45:13-19.
17. Gnecchi M., Zhang Z., Ni A., Dzau V.J. Paracrine mechanisms in adult stem cell signaling and therapy. Circ. Res. 2008, 103:1204-1219.
18. Herberts C.A., Kwa M.S., Hermsen H.P. Risk factors in the development of stem cell therapy. J. Transl. Med. 2011, 9:29.
19. Hisanaga T., Terai S., Iwamoto T., Takami T., Yamamoto N., Murata T., Matsuyama T., Nishina H., Sakaida I. TNFR1-mediated signaling is important to induce the improvement of liver fibrosis by bone marrow cell infusion. Cell Tissue Res. 2011, 346:79-88.
20. Hsiao S.T., Asgari A., Lokmic Z., Sinclair R., Dusting G.J., Lim S.Y., Dilley R.J. Comparative analysis of paracrine factor expression in human adult mesenchymal stem cells derived from bone marrow, adipose, and dermal tissue. Stem Cells Dev. 2012, 21:2189-2203.
21. Ismail Z.M., Kamel A.M., Yacoub M.F., Aboulkhair A.G. The effect of in vivo mobilization of bone marrow stem cells on the pancreas of diabetic albino rats (a histological & immunohistochemical study). Int. J. Stem Cells 2013, 6:1-11.
22. Inderbitzin D., Beldi G., Sidler D., Studer P., Keogh A., Bisch-Knaden S., Weimann R., Kappeler A., Gloor B., Candinas D. Granulocyte colony-stimulating factor supports liver regeneration in a small-for-size liver remnant mouse model. J. Gastrointest. Surg. 2007, 11:280-285.
23. Jensen G.S., Hart A.N., Zaske L.A., Drapeau C., Gupta N., Schaeffer D.J., Cruickshank J.A. Mobilization of human CD34+ CD133+ and CD34+ CD133(-) stem cells in vivo by consumption of an extract from Aphanizomenon flos-aquae--related to modulation of CXCR4 expression by an l-selectin ligand?. Cardiovasc. Revasc. Med. 2007, 8:189-202.
24. Joshi M., Oltean M., Patil P.B., Hallberg D., Kleman M., Holgersson J., Olausson M., Sumitran-Holgersson S. Chemokine-mediated robust augmentation of liver engraftment: a novel approach. Stem Cells Transl. Med. 2015, 4:21-30.
25. Kharaziha P., Hellstrom P.M., Noorinayer B., Farzaneh F., Aghajani K., Jafari F., Telkabadi M., Atashi A., Honardoost M., Zali M.R., Soleimani M. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur. J. Gastroenterol. Hepatol. 2009, 21:1199-1205.
26. Kurdi M., Booz G.W. G-CSF-based stem cell therapy for the heart-unresolved issues part A: paracrine actions, mobilization, and delivery. Congest. Heart Fail. 2007, 13:221-227.
27. Lehman E.M., Wilson M.L. Epidemic hepatitis C virus infection in Egypt: estimates of past incidence and future morbidity and mortality. J. Viral Hepat. 2009, 16:650-658.
28. Mark A.L., Sun Z., Warren D.S., Lonze B.E., Knabel M.K., Melville Williams G.M., Locke J.E., Montgomery R.A., Cameron A.M. Stem cell mobilization is life saving in an animal model of acute liver failure. Ann. Surg. 2010, 252:591-596.
29. Majka M., Janowska-Wieczorek A., Ratajczak J., Ehrenman K., Pietrzkowski Z., Kowalska M.A., Gewirtz A.M., Emerson S.G., Ratajczak M.Z. Numerous growth factors, cytokines, and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood 2001, 97:3075-3085.
30. Mizunaga Y., Terai S., Yamamoto N., Uchida K., Yamasaki T., Nishina H., Fujita Y., Shinoda K., Hamamoto Y., Sakaida I. Granulocyte colony-stimulating factor and interleukin-1beta are important cytokines in repair of the cirrhotic liver after bone marrow cell infusion: comparison of humans and model mice. Cell Transplant. 2012, 21:2363-2375.
31. Nakamura T., Sakata R., Ueno T., Sata M., Ueno H. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology 2000, 32:247-255.
32. Nakamura T., Ueno T., Sakamoto M., Sakata R., Torimura T., Hashimoto O., Ueno H., Sata M. Suppression of transforming growth factor-beta results in up-regulation of transcription of regeneration factors after chronic liver injury. J. Hepatol. 2004, 41:974-982.
33. Nejak-Bowen K., Orr A., Bowen W.C., Michalopoulos G.K. Conditional genetic elimination of hepatocyte growth factor in mice compromises liver regeneration after partial hepatectomy. PLOS ONE 2013, 8:e59836.
34. Ortiz L.A., Dutreil M., Fattman C., Pandey A.C., Torres G., Go K., Phinney D.G. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:11002-11007.
35. Pusztaszeri M.P., Seelentag W., Bosman F.T. Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J. Histochem. Cytochem. 2006, 54:385-395.
36. Quintana-Bustamante O., Alvarez-Barrientos A., Kofman A.V., Fabregat I., Bueren J.A., Theise N.D., Segovia J.C. Hematopoietic mobilization in mice increases the presence of bone marrow-derived hepatocytes via in vivo cell fusion. Hepatology 2006, 43:108-116.
37. Ripa R.S., Haack-Sorensen M., Wang Y., Jorgensen E., Mortensen S., Bindslev L., Friis T., Kastrup J. Bone marrow derived mesenchymal cell mobilization by granulocyte-colony stimulating factor after acute myocardial infarction: results from the Stem Cells in Myocardial Infarction (STEMMI) trial. Circulation 2007, 116:I24-I30.
38. Salama H., Zekri A.R., Bahnassy A.A., Medhat E., Halim H.A., Ahmed O.S., Mohamed G., Al Alim S.A., Sherif G.M. Autologous CD34+ and CD133+ stem cells transplantation in patients with end stage liver disease. World J. Gastroenterol. 2010, 16:5297-5305.
39. Salama H., Zekri A.R., Medhat E., Al Alim S.A., Ahmed O.S., Bahnassy A.A., Lotfy M.M., Ahmed R., Musa S. Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease. Stem Cell Res. Ther. 2014, 5:70.
40. Saito T., Tomita K., Haga H., Okumoto K., Ueno Y. Bone marrow cell-based regenerative therapy for liver cirrhosis. World J. Methodol. 2013, 3:65-69.
41. Singh V., Sharma A.K., Narasimhan R.L., Bhalla A., Sharma N., Sharma R. Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. Am. J. Gastroenterol. 2014, 109:1417-1423.
42. Takami T., Terai S., Sakaida I. Stem cell therapy in chronic liver disease. Curr. Opin. Gastroenterol. 2012, 28:203-208.
43. Togel F., Hu Z., Weiss K., Isaac J., Lange C., Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am. J. Physiol. Ren. Physiol. 2005, 289:F31-F42.
44. Trak-Smayra V., Contreras J., Dondero F., Durand F., Dubois S., Sommacale D., Marcellin P., Belghiti J., Degott C., Paradis V. Role of replicative senescence in the progression of fibrosis in hepatitis C virus (HCV) recurrence after liver transplantation. Transplantation 2004, 77:1755-1760.
45. Tsolaki E., Athanasiou E., Gounari E., Zogas N., Siotou E., Yiangou M., Anagnostopoulos A., Yannaki E. Hematopoietic stem cells and liver regeneration: differentially acting hematopoietic stem cell mobilization agents reverse induced chronic liver injury. Blood Cells Mol. Dis. 2014, 53:124-132.
46. Wan Z., You S., Rong Y., Zhu B., Zhang A., Zang H., Xiao L., Xie G., Xin S. CD34+ hematopoietic stem cells mobilization, paralleled with multiple cytokines elevated in patients with HBV-related acute-on-chronic liver failure. Dig. Dis. Sci. 2013, 58:448-457.
47. Wang J., Zhou X., Cui L., Yan L., Liang J., Cheng X., Qiao L., Shi Y., Han Z., Cao Y., Han Y., Fan D. The significance of CD14+ monocytes in peripheral blood stem cells for the treatment of rat liver cirrhosis. Cytotherapy 2010, 12:1022-1034.
48. Wang Y., Lian F., Li J., Fan W., Xu H., Yang X., Liang L., Chen W., Yang J. Adipose derived mesenchymal stem cells transplantation via portal vein improves microcirculation and ameliorates liver fibrosis induced by CCl4 in rats. J. Transl. Med. 2012, 10:133.
49. Weissman I.L., Anderson D.J., Gage F. Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations. Annu. Rev. Cell Dev. Biol. 2001, 17:387-403.
50. Xing T.J., Xu H.T., Xian J.C., Shen M.L., Li H., Ye J., Zhang L.X. Mechanism and efficacy of mobilization of granulocyte colony-stimulating factor in the treatment of chronic hepatic failure. Hepatogastroenterology 2013, 60:170-175.
51. Yannaki E., Athanasiou E., Xagorari A., Constantinou V., Batsis I., Kaloyannidis P., Proya E., Anagnostopoulos A., Fassas A. G-CSF-primed hematopoietic stem cells or G-CSF per se accelerate recovery and improve survival after liver injury, predominantly by promoting endogenous repair programs. Exp. Hematol. 2005, 33:108-119.
52. Yuan S., Jiang T., Sun L., Zheng R., Ahat N., Zhang Y. The role of bone marrow mesenchymal stem cells in the treatment of acute liver failure. Biomed. Res. Int. 2013, 2013:251846.
53. Zhang L., Kang W., Lei Y., Han Q., Zhang G., Lv Y., Li Z., Lou S., Liu Z. Granulocyte colony-stimulating factor treatment ameliorates liver injury and improves survival in rats with d-galactosamine-induced acute liver failure. Toxicol. Lett. 2011, 204:92-99.
54. Zhang L., Ye J.S., Decot V., Stoltz J.F., de Isla N. Research on stem cells as candidates to be differentiated into hepatocytes. Biomed. Mater. Eng. 2012, 22:105-111.